Startups
AimedBio
AimedBio is a South Korean biotechnology company spun out of Samsung Medical Center that develops antibody-based cancer therapies, including antibody-drug conjugates. Its P-ADC platform combines patient-derived data and disease models to identify targets, validate candidates and build precision oncology medicines. Its pipeline includes the FGFR3-targeted ADC AMB302/BHV-1530 for solid tumors including glioblastoma, licensed to Biohaven, and additional ADC and bispecific ADC candidates. The company also develops payload technologies and blood-brain-barrier delivery partnerships; it listed on KOSDAQ in December 2025.
Founded 2018